Journal
ENDOCRINE
Volume 71, Issue 1, Pages 158-167Publisher
SPRINGER
DOI: 10.1007/s12020-020-02501-3
Keywords
Acromegaly; GH receptor antagonist; Somatostatin analogs; Combination therapy
Categories
Funding
- Pfizer Inc.
- Pfizer
Ask authors/readers for more resources
The study aimed to define the medical reasons for treating patients with Pegvisomant (PEG) as monotherapy or combined therapy with somatostatin analogs (SAs). Results showed different patterns of treatment based on patient characteristics and response to therapy, with a focus on tumor concern and ease of normalizing IGF-I levels. Overall, the prospect of reducing PEG injection frequency favored the choice of combined therapy in certain cases.
Objective After surgery, when somatostatin analogs (SAs) do not normalise IGF-I, pegvisomant (PEG) is indicated. Our aim was to define the medical reasons for the treatment of patients with PEG as monotherapy (M) or combined with SA, either as primary bitherapy, PB (PEG is secondarily introduced after SA) or as secondary bitherapy, SB (SAs secondarily introduced after PEG). Methods We retrospectively analysed French data from ACROSTUDY. Results 167, 88 and 57 patients were treated with M, PB or SB, respectively, during a median time of 80, 42 and 70 months. The median PEG dose was respectively 15, 10 and 20 mg. Before PEG, the mean IGF-I level did not differ between M and PB but the proportion of patients with suprasellar tumour extension was higher in PB group (67.5% vs. 44.4%,P = 0.022). SB regimen was used preferentially in patients with tumour increase and IGF-I level difficult to normalise under PEG. In both secondary regimens, the decrease of the frequency of PEG's injections, compared to monotherapy was confirmed. However, the mean weekly dose of PEG between M and PB remained the same. Conclusions The medical rationale for continuing SAs rather than switching to PEG alone in patients who do not normalise IGF-I under SAs was a tumour concern with suprasellar extension and tumour shrinkage under SA. A potential explanation for introducing SA in association with PEG appears to be a tumour enlargement and difficulties to normalise IGF-I levels under PEG given alone. In both regimens, the prospect of lowering PEG injection frequency favoured the choice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available